secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001558370-24-001431
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos reports record Q4 net sales $82.4M, up 16% YoY; FY2023 sales $314.7M, up 11%
--------------------------------------------------------------------------------

- Record Q4 2023 net sales $82.4M, up 16% YoY; glaucoma $60.6M (+15%), corneal health $21.8M (+19%).
- Q4 GAAP net loss $36.8M ($0.75/share) vs $31.5M ($0.66) YoY; non-GAAP loss $30.6M ($0.63).
- Full-year 2023 net sales $314.7M, up 11% YoY; net loss $134.7M ($2.78/share) vs $99.2M ($2.09) in 2022.
- Ended Q4 with $301M cash, equivalents & short-term investments; reaffirmed 2024 net sales guidance $350M-$360M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/0001558370-24-001431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/gkos-20240221x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer